tbuckley/cabot-search huggingface dataset:
Reply
Authors: Benz Edmund W., Moses Harold L.
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Reply Get access Benz Edmund W., Jr., Benz Edmund W., Jr. Department of Experimental Pathology and Anatomy Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55901 Search for other works by this author on: Oxford Academic PubMed Google Scholar Moses Harold L. Moses Harold L. Department of Experimental Pathology and Anatomy Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55901 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 54, Issue 6, June 1975, Pages 1495–1496, https://doi.org/10.1093/jnci/54.6.1495a Published: 01 June 1975
Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors.
Authors: Cheryl L Rock, Shirley Flatt, Tim Byers, Graham A. Colditz, Wendy Demark-Wahnefried, Patricia A. Ganz, Kathleen Y. Wolin, Anthony D. Elias, Helen Krontiras, Jingxia Liu, Michael Naughton, Bilge Pakiz, Barbara A. Parker, Rebecca L. Sedjo, Holly Wyatt
Journal: Journal of Clinical Oncology (2015)

9506 Background: Obesity increases risk for all-cause and breast cancer mortality and co-morbidities in women who have been diagnosed and treated for breast cancer. The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Study is the largest weight loss intervention trial among breast cancer survivors to date. Methods: In this multi-center randomized trial, 692 overweight/obese women, who were on average 2 years post-primary treatment for early stage breast cancer, were randomized to a group-based cognitive-behavioral intervention with telephone counseling and tailored newsletters to support weight loss or a less intensive (control) intervention and followed for 2 years. The primary endpoint for this randomized controlled trial was weight loss measured at both 1- and 2-year follow-up. Secondary aims included the exploration of effect modifiers (such as time since diagnosis and type of tumor and therapy) on weight loss at 24 months. Weight and blood pressure were measured at 6, 12, 18, and 24 months. Longitudinal mixed models were used to analyze change over time. Results: At 12 months, mean weight loss was 6.0% of initial weight in the intervention group and 1.5% in the control group (P < .0001). At 24 months, mean weight loss in the intervention and control groups was 3.7% and 1.3%, respectively (P < .0001). Physical activity increased significantly in intervention vs. control women at 6 and 12 months (P < .0001). Blood pressure (diastolic and systolic) was lower in the intervention vs. control groups at follow-up clinic visits (P < .05). The weight loss intervention was more effective among women older than 55 years than among younger women. Conclusions: A behavioral weight loss intervention can lead to clinically meaningful weight loss in overweight/obese breast cancer survivors. These findings support the need to conduct additional studies to test methods to support sustained weight loss. They also underscore the need for larger, longer-term trials to test the effects of intentional weight loss on breast cancer recurrence and survival. Clinical trial information: NCT01112839.
Brain Injury in Boxing
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Donor Dopamine Pretreatment and Graft Function After Kidney Transplantation—Reply
Authors: Peter Schnuelle
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trauma Registry
Authors: David R. Boyd
Journal: JAMA (1973)

One of the major problems in providing improved care for the injured patient is the lack of a well-defined system of care for the critically injured. Patients are ordinarily taken to the nearest hospital, rather than the one best equipped and staffed to treat them. Many of these patients are later transferred to more appropriate facilities with considerable discomfort, disability, and even death resulting from these unnecessary movements. Many patients are given suboptimal care once they reach an inadequate facility. A major barrier to improving trauma care is the lack of cumulative knowledge and experience in the complex management of severely injured trauma patients. The general inadequacy of the present medical record system further compounds this problem. In response to this obvious deficiency and at the suggestion of the National Research Council,<sup>1</sup>a computerized Trauma Registry has been developed at the Trauma Unit of the Cook County Hospital, the
Heberden Society: ANNUAL REPORT, 1966
Authors: D Brewerton, H Currey, K Walton, E Coomes, H Muir, J Holborrow, F Gibberd, J Bradley, A Franks, D Gardner, F Steven, R Grahame, Prof Bamett, G Fostiropoulos, J Topp, J Gomez, S Gokarn
Journal: Annals of the Rheumatic Diseases (1967)
PRAGTICAL NOTES.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract ES5-1: Tumor dormancy and recurrence
Authors: L Chodosh
Journal: Cancer Research (2019)

Abstract Despite early detection and adjuvant therapy, breast cancer remains the leading cause of cancer mortality in women, largely due to distant, incurable recurrences that arise years, or even decades, after treatment of the primary tumor. Recurrent, metastatic tumors arise from the pool of residual local and disseminated tumor cells (DTCs) that survive primary treatment in tissues at sites throughout the body where they persist in a presumed dormant state. Early studies demonstrated that an immunohistochemical assay can detect cytokeratin-positive DTCs in bone marrow aspirates of a substantial fraction of breast cancer patients lacking any clinical signs of metastasis. Importantly, women who harbor detectable DTCs in their bone marrow have a substantially increased risk of distant recurrence, as well as poorer breast cancer-specific and overall survival, and this measure has repeatedly been shown to be an independent predictor of recurrence-free survival and overall survival in multivariate analysis. Since DTCs constitute the reservoir from which recurrent cancers arise, understanding their biology is a critical priority in cancer research. We hypothesize that effectively disabling the survival mechanisms by which DTCs persist in breast cancer patients following treatment will deplete this critical reservoir of cells, reduce tumor recurrence, and thereby improve survival. At present, however, the mechanisms enabling these cells to survive in a dormant state and ultimately recur are poorly understood and clinical methods to detect DTCs, as well as DTC-directed therapeutic approaches, are still in their infancy. To address this critical gap and elucidate critical pathways in dormant tumor cell survival, we and others have developed a variety of mouse models for human breast cancer that recapitulate key features of human breast cancer progression, including metastasis, residual disease, dormancy and recurrence. Investigation of these models using both genetic and pharmacological approaches has identified several mediators of dormant DTC survival and recurrence, demonstrated their relevance to pathways that contribute to therapeutic resistance in human breast cancers following targeted therapy or chemotherapy, and revealed that pharmacological targets for dormancy and recurrence may be unique to these stages of tumor progression. These findings have, in turn, led to the initiation of clinical trials to test the ability of targeted therapies to deplete the burden of DTCs in the bone marrow of breast cancer patients and thereby decrease risk of relapse. If successful, the ability to therapeutically target survival mechanisms utilized by DTCs would constitute a powerful, paradigm-shifting approach to preventing cancer recurrence and the mortality associated with it. Citation Format: Chodosh L. Tumor dormancy and recurrence [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES5-1.
Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).
Authors: C. W. Reuter, V. Gruenwald, P. Ivanyi, M. A. Morgan, M. Fenner, A. Ganser
Journal: Journal of Clinical Oncology (2010)

4682 Background: There is no proven, effective, standard second-line chemotherapy for castration- and docetaxel (D)-resistant prostate cancer (DRPC). Recent data suggest that carboplatin (C) may be effective in combination with docetaxel in this setting, however, the optimal DC-based regimen is still unclear. Methods: Docetaxel failure/resistance was defined according to the Prostate Cancer Working Group (PCWG2 2007) criteria. Since February 2005, 43 consecutive DRPC pts were treated with at least two cycles of C AUC5 iv on day 1 and D at a dose of 35 mg/m2 iv on days 1, 8, 15 q4w after receiving informed consent until disease progression or occurrence of intolerable adverse effects. Results: Decreased prostate-specific antigen (≥50% PSA) was observed in 22/43 (51.2%, 95% CI, 35.5, 66.7%) patients, with ≥90% reduction in 12/43 patients (27.9%). Of 21 patients with measureable disease, 8 patients exhibited partial remission (all PSA responder, PSAR), 9 showed stable disease (6 PSAR) and 4 showed progressive disease (PD) (all PSANR). At the time of analysis the median follow-up time for all patients was 10.4 months. Median progression-free survival (PFS) for all patients was 6.5 months (CI 95% 4.1, 8.9) and median overall survival (OS) was 15.8 months (CI 95% 12.1, 18.5). In PSAR, PFS was 9.5 (CI 95% 4.2, 14.9) months versus 3.3 (CI 95% 2.6, 4.0) months in PSANR (p<0.001; hazard ratio HR 0.108) and OS was 24.4 months (CI 95% 19.5, 29.4) versus 7.8 (CI 95% 5.2, 10.3) months (p=0.001; HR 0.232). In multivariable analyses, PSA response was associated with lower Gleason sum (≤8) and presence of onycholysis. PFS was associated with lower baseline PSA at castration- resistant status (PSA-CR <100 μ g/l), LDH and PSA response ≥50%. OS was associated with lower NSE(<20 μ g/l), lower PSA-CR and PSA at docetaxel-resistant status (<100 μ g/l), and absence of extraosseous metastasis. This regimen was reasonably well tolerated, with leukopenia/neutropenia as the most common reversible grade 3/4 toxicity (41.9/39.5%). Conclusions: These data suggest that weekly docetaxel plus carboplatin may be an important therapeutic second-line treatment option for DRPC patients. No significant financial relationships to disclose.
Neoadjuvant use of 5-fluorouracil, epirubicin and cyclophosphamide with and without celecoxib for locally advanced breast cancer: A phase II study correlating response to celecoxib with high levels of COX-2 gene expression in the tumor
Authors: L. W. Chow, M. Toi, Y. Takebayashi
Journal: Journal of Clinical Oncology (2004)

9603
Symposium on Biomedical Dosimetry: Physical Aspects, Instrumentation, Calibration
Journal: JNCI Journal of the National Cancer Institute (1979)

Symposium on Biomedical Dosimetry: Physical Aspects, Instrumentation, Calibration Get access JNCI: Journal of the National Cancer Institute, Volume 63, Issue 6, December 1979, Page 1493, https://doi.org/10.1093/jnci/63.6.1493-c Published: 01 December 1979
Erratum
Journal: JNCI Journal of the National Cancer Institute (1991)

“Helicobacter pylori Infection in Intestinal-and Diffuse-Type Gastric Adenocarcinomas” by Julie Parsonnct, et al. [J Natl Cancer Inst 83:640–643, 1991 (Issue 9)]. The figures in this report were reversed. The figure over the legend entitled “Figure 1” should be above the legend entitled “Figure 2” and vice versa. The Journal regrets this error.
Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction
Authors: R. F. Spark
Journal: JAMA (1980)

The concept that impotence is psychogenic in 95% of cases is reconsidered. Screening serum testosterone levels of 105 consecutive patients with impotence showed that 37 patients had previously unsuspected disorders of the hypothalamic-pituitary-gonadal axis. Twenty patients had hypogonadotropic-hypogonadism, seven had hypergonadotropic-hypogonadism, eight had hyperprolactinemia, and two had occult hyperthyroidism. Once the specific defect was defined, appropriate therapy was instituted, and potency was restored in 33 patients. Screening serum testosterone levels is useful in identifying hypothalamic-pituitary-gonadal dysfunction in patients with impotence. (<i>JAMA</i>243:750-755, 1980)
The impact of open colectomy on resection of colorectal liver metastases.
Authors: Stuart Michael Robinson, Lucas Arlott, Gourab Sen, Jeremy J. French, Richard M. Charnley, Derek M. Manas, Steve A. White
Journal: Journal of Clinical Oncology (2015)

783 Background: Laparoscopic liver resection (LLR) is increasingly utilized in the management of patients with metastatic colorectal cancer. The aim of this study was to determine the impact of open vs. colonic resection of the primary tumour on outcomes following LLR. Methods: A prospectively maintained database was searched to identify all patients undergoing laparoscopic resection for colorectal liver metastases (CRLM) between 1/1/2007 and 31/12/2013. Demographic, histological, surgical outcome and survival data were collated retrospectively. Statistical analysis was performed using SPSS. Results: A total of 71 patients (median age 66 yr; 64% male) underwent resection in this study of whom 35 had a laparoscopic colectomy (LC). The presence of a previous open colectomy (OC) surgical morbidity (17% vs. 11%; p=0.53); conversion to open surgery (22% both groups; p=0.95); duration of surgery (240 min vs. 285 min; p=0.28); or length of hospital stay (5 vs. 6 days; p=0.98). Overall survival in this series was 47 months with no difference between groups (p=0.58). Patients who underwent OC appeared to have a poorer recurrence free survival (8 vs. 21 months; p=0.03) although on multivariate analysis the only factor predictive of early recurrence was a node positive primary (OR 3.8; p=0.05). Conclusions: In patients being considered for LLR for metastasic colorectal cancer the surgical approach to colectomy has no bearing on either short term surgical outcomes or longer term disease specific survival.
The Human Hemoglobins in Health and Disease
Authors: Amoz I. Chernoff
Journal: New England Journal of Medicine (1955)

IN 1949 Pauling and his associates1 described sickle-cell hemoglobin and introduced into medicine the concept of the molecular disease, a concept that implies that certain diseases are caused by genetically determined abnormalities of protein synthesis. Progress in the study of the human hemoglobins, and of the molecular diseases that they cause, has been so rapid in the past six years that it seems advisable to review the available information in this field and to attempt a correlation of the many clinical and hematologic observations related to these syndromes.Several excellent reviews of the biochemical aspects of the abnormal hemoglobins have . . .
Synergism in Carcinogenesis: Reply
Authors: Arnold E. Reif
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Synergism in Carcinogenesis: Reply Get access Arnold E. Reif Arnold E. Reif Mallory Institute of Pathology, Boston University School of Medicine, Boston City Hospital, Boston, Massachusetts 02118 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 74, Issue 3, March 1985, Page 729, https://doi.org/10.1093/jnci/74.3.729-a Published: 01 March 1985
COUGHS AND COLDS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia Evan Stein, Kristina L. Strutt, Elinor Miller, Harry Southworth. Metabolic and Atherosclerosis Research Center, Cincinnati, OH, AstraZeneca, Macclesfield, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
The Practice of Medicine.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The stomach in pseudoxanthoma elasticum
Authors: A. E. Cocco
Journal: JAMA (1969)

A gastroscopic examination was performed on five patients with pseudoxanthoma elasticum (PXE) and a history of upper-gastrointestinal tract bleeding. All five had linear or nodular, raised, submucosal lesions which were yellow in color and similar to the xanthomalike skin lesions seen in this disease. In addition, two patients had moderately severe gastritis. In view of the high incidence of gastrointestinal bleeding and a presumed defect in the vascular component of clotting in their disease, it is suggested that all patients with PXE be examined by gastroscopy and treated intensively with antacids if gastritis exists.
EFFICACY AND THE FOOD AND DRUG ADMINISTRATION
Journal: JAMA (1961)

"The marketing of a relatively useless drug is infinitely less serious than would be the arbitrary exclusion from the market of a drug that might have been life saving for many persons." This sentence appears in the AMA testimony on S. 1552 presented by Dr. Hugh Hussey, Chairman of the Board of Trustes, on July 5 to the Kefauver Subcommittee on Antitrust and Monopoly. The entire statement appears on page 190. The section of the bill of greatest concern to the practice of medicine relates to efficacy. Since the adoption of the present Food, Drug, and Cosmetic Act in 1938, the Food and Drug Administration has reviewed applications for the marketing of a new prescription drug and approved or disapproved these applications on the basis of safety. In addition, FDA has had the authority to cause the withdrawal of a prescription drug from the market because of "mislabeling." In its